Original Shark, Kevin Harrington, Joins FSD Pharma to Unleash His Iconic Entrepreneurial Skills!

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is proud to announce the addition of Kevin Harrington, an iconic entrepreneur, to its Advisory Board. As a biopharmaceutical company committed to developing innovative treatments for neurodegenerative, inflammatory, and metabolic disorders, the Company is thrilled to welcome the expertise and vision of a leader like Harrington to its team.

Mr. Harrington is a legend in the world of business. He is the inventor of the infomercial, a pioneer of the “As Seen on TV” brand, and an original “shark” on ABC’s hit show “Shark Tank.” His impressive career has seen him launch over 20 businesses that have each generated sales in excess of $100 million, while introducing more than 1,000 products that have earned over $6 billion in global sales. His business ventures are truly global, having opened distribution outlets in over 100 countries.

Kevin has long been a leader in the marketing space, earning the respect of companies for his expertise, network, and business acumen. We at FSD Pharma are thrilled to welcome him to our Advisory Board and look forward to leveraging his experience and knowledge to further our research and development initiatives.

With an eye for ground-floor opportunities in research and development, Mr. Harrington has made investments with the potential to be truly transformational, from beverages to kitchen utensils to FSD Pharma’s strong pipeline of therapeutics. His latest venture aims to make an important societal impact by providing potential products that can help with alcohol misuse cases. Mr. Harrington is passionate about this mission and welcomes the chance to make a difference.

Renowned author, influencer, and marketing maven, Mr. Harrington is the co-founder of the Entrepreneurs’ Organization, a renowned global network of more than 17,000 business leaders spanning 220 chapters in 60 countries. His frequent media appearances and citations in prominent outlets have solidified his position as an industry leader. With his experience and vast network of contacts, Mr. Harrington will be leveraging his expertise to expand the reach of the company, both within the beverage industry and beyond. To further strengthen the company’s profile, Mr. Harrington is also in the process of building a powerful Advisory Board, with the addition of other high-profile business minds.

FSD is pleased to announce the granting of stock options to certain of its employees, which will allow them to purchase up to an aggregate of 500,000 Class B subordinate voting shares at a price of C$2.45 per share. These options, which are valid for three years from the date of grant, will allow employees to benefit from the Company’s future success. In addition, FSD has agreed to issue common share purchase warrants that entitle the holder to purchase up to 1,000,000 shares of the Company at an exercise price ranging from $1.75 USD to $8.00 USD, with the warrants expiring 24 months after the vesting criteria has been met.

About FSD Pharma

FSD Pharma Inc. is a biotechnology firm with a mission to develop innovative treatments for inflammatory diseases and mental health disorders. Its lead compound, FSD201, is a proprietary ultra-micronized PEA formulation designed to tackle inflammation. To expand its focus on mental health, FSD Pharma has established two wholly owned subsidiaries: FSD BioSciences, Inc. and Lucid Psychss Inc. FSD BioSciences is researching the potential of FSD201, while Lucid Psychss is developing its lead compounds Lucid-Psych and Lucid-MS, which could be used to treat mental health disorders and neurodegenerative diseases, respectively. By exploring the potential of these drug candidates, FSD Pharma is seeking to revolutionize the way we treat these diseases.

Leave a Comment